Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease

NCT01484574 is registered in ClinicalTrials.gov with Stempeutics Research Pvt Ltd as lead sponsor.

NCT NCT01484574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01484574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease
Lead sponsor
Stempeutics Research Pvt Ltd
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
March 31, 2016
Enrollment
90 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

buerger's disease, critical limb ischemia